Clinical trial
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study
NCT07554222 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- April 18, 2026
- Completion date
- December 31, 2028
- Enrollment
- 160 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
active non-segmental vitiligo, healthy, severe alopecia areata